This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Sucampo Pharmaceuticals, Inc.

Drug Names(s): UV 002, UV002

Description: UV-002 is a vascular adhesion protein-1 (VAP-1) inhibitor.

VAP-1, or semicarbazide sensitive amine oxidase (SSAO) is a protein present in the vascular epithelium as a membrane-binding molecule or in the serum as free molecules. The VAP-1/SSAO inhibitor controls excessive VAP-1/SSAO and normalizes its functions.

Deal Structure: R-Tech and Sucampo
In August 2015, Sucampo Pharmaceuticals announced the launch of an all-cash tender offer in Japan and the execution of a separate share purchase agreement with certain shareholders of R-Tech Ueno to acquire all outstanding shares of R-Tech Ueno for a total consideration of JPY 33 billion, or approximately $278 million, inclusive of approximately $54 million in cash and 2.5 million Sucampo shares, held by R-Tech Ueno.

In December 2015, Sucampo Pharmaceuticals announced the completion of its acquisition of R-Tech Ueno and all remaining outstanding shares. Sucampo acquired R-Tech Ueno for 32.8 billion Japanese Yen (JPY), or approximately $275 million.

UV-002 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug